April 14 (Reuters) -
VIVUS ANNOUNCES ENROLLMENT OF FIRST PATIENT IN PHASE 2 CLINICAL TRIAL ASSESSING ETHANOL-FREE CARMUSTINE AS A COMPONENT OF HIGH-DOSE CHEMOTHERAPY PRIOR TO TRANSPLANT IN PATIENTS WITH HODGKIN OR NON-HODGKIN LYMPHOMA
Further company coverage: [ ]